B-cell function suppression

"B-cell function suppression" is **not the name of a specific molecule or receptor**, but rather describes a biological process or therapeutic strategy aimed at reducing or inhibiting the activity of B lymphocytes. This can be achieved through various means—such as monoclonal antibodies against surface markers like CD19, CD20, and CD22; inhibitors of survival factors like BAFF and APRIL; or proteasome inhibitors that target plasma cells[1][4]. Suppressing B cell function is an important approach in treating autoimmune diseases and certain cancers where pathogenic antibody production or immunoregulatory roles of B cells contribute to disease pathology[1][2][4]. However, there is no single protein, gene product, receptor, enzyme, transporter etc. called "B-cell function suppression." Instead, this term refers to the outcome produced by targeting various molecular components involved in B cell biology. **Therapeutic context:** Drugs such as rituximab (anti-CD20), belimumab (anti-BAFF), and bortezomib are used to suppress different aspects of B cell activity[1][4]. The mechanism may involve depletion of specific subpopulations or inhibition of survival signals. These interventions are relevant in autoimmune conditions like systemic lupus erythematosus and rheumatoid arthritis[1][4], as well as some cancers where regulatory B cells suppress anti-tumor immunity[2]. **Conclusion:** Because "B-cell function suppression" does not refer to a discrete molecular entity but rather an immunological process/therapeutic goal involving multiple targets and pathways[1][2][3], it should **not be considered a canonical therapeutic target** itself. If you seek structured information on actual drug targets involved in this process—such as CD20 ("Cluster of differentiation 20"), BAFF ("B cell activating factor"), etc.—please specify one such molecule. > “Generally, conventional immunosuppressive therapy…partly inhibits autoantibody production…several drugs that specifically target B cells…are either in clinical use or under development…” [1] > “This review seeks to summarize cutting-edge modalities for targeting B cells…” [4]